Literature DB >> 24622040

Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure.

Klaudia Vyskocilova1, Lenka Spinarova1, Jindrich Spinar2, Tereza Mikusova1, Jiri Vitovec1, Josef Malek3, Filip Malek4, Ales Linhart5, Marian Fedorco6, Petr Widimsky7, Cestmir Cihalik8, Jiri Parenica2, Simona Littnerova9, Jiri Jarkovsky9.   

Abstract

AIMS: Liver pathology caused by cardiac dysfunction is relatively well recognized, however, its clinical importance has not been fully evaluated. The aim of this study was to assess the prevalence of liver function tests (LFTs) abnormalities and to identify associated factors mediating hepatic impairment in patients with acute heart failure (AHF).
METHODS: The AHEAD (Acute Heart Failure Database) registry is a database conducted in 9 university hospitals and 5 regional health care facilities in the Czech Republic. From December 2004 to October 2012, the data of 8818 patients were included. The inclusion criteria for the database followed the European guidelines for AHF. Serum activities of all LFTs and total bilirubin were available in 1473 patients at the baseline.
RESULTS: In patients with AHF, abnormal LFTs were seen in 76% patients (total bilirubin in 34%, γ-glutamyltransferase in 44%, alkaline phosphatase in 20%, aspartate aminotransferase in 42%, alanine aminotransferase in 35%). Patients with cardiogenic shock were more likely to have LFTs abnormalities compared to mild AHF and pulmonary oedema. LFTs abnormalities were strongly associated with AHF severity (left ventricular ejection fraction and NYHA functional class) and clinical manifestation. While hepatocellular LFTs pattern predominated in left sided forward AHF, cholestatic profile occurred mainly in bilateral and right sided AHF. Additionally, patients with moderate to severe tricuspid regurgitation had significantly higher prevalence of abnormalities in cholestatic LFTs.
CONCLUSIONS: Defining the LFTs profile typical for AHF plays an important role in management of AHF patients, since it may avoid redundant hepatic investigations and diagnostic misinterpretations.

Entities:  

Keywords:  bilirubin; congestive hepatopathy; heart failure; ischemic hepatitis; liver function tests

Mesh:

Substances:

Year:  2014        PMID: 24622040     DOI: 10.5507/bp.2014.014

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  6 in total

Review 1.  Cardiohepatic syndrome: liver injury in decompensated heart failure.

Authors:  Said Laribi; Alexandre Mebazaa
Journal:  Curr Heart Fail Rep       Date:  2014-09

2.  Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial.

Authors:  Weihao Liang; Xin He; Dexi Wu; Ruicong Xue; Bin Dong; Marvin Owusu-Agyeman; Jingjing Zhao; Linnuan Cai; Zhiyao You; Yugang Dong; Chen Liu
Journal:  Front Cardiovasc Med       Date:  2021-05-12

3.  Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials.

Authors:  D M Longo; G T Generaux; B A Howell; S Q Siler; D J Antoine; D Button; A Caggiano; A Eisen; J Iaci; R Stanulis; T Parry; M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-05-27       Impact factor: 6.875

Review 4.  Diagnosis of Acute Heart Failure in the Emergency Department: An Evidence-Based Review.

Authors:  Brit Long; Alex Koyfman; Michael Gottlieb
Journal:  West J Emerg Med       Date:  2019-10-24

5.  Use and diagnostic value of liver enzyme tests in the emergency department and subsequent heart failure diagnosis: a retrospective cohort study.

Authors:  Elena Vasti; Jeffrey A Tabas; Ari Hoffman; Mark Pletcher
Journal:  BMJ Open       Date:  2022-03-30       Impact factor: 2.692

6.  Diagnosis and management of acute heart failure.

Authors:  Dilek Ural; Yüksel Çavuşoğlu; Mehmet Eren; Kurtuluş Karaüzüm; Ahmet Temizhan; Mehmet Birhan Yılmaz; Mehdi Zoghi; Kumudha Ramassubu; Biykem Bozkurt
Journal:  Anatol J Cardiol       Date:  2015-11       Impact factor: 1.596

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.